Dr. Asish Bhaumik is an Associate Professor in the Department of Pharmaceutical Chemistry at the School of Pharmaceutical Sciences (SOPS), Girijananda Chowdhury University (GCU), Tezpur, Assam, where he joined on March 15, 2023. He teaches courses such as Medicinal Chemistry, Pharmaceutical Organic Chemistry, Therapeutic Chemistry, Biochemistry, and Pharmaceutical Analysis. Dr. Bhaumik earned his Ph.D. in Pharmaceutical Science with a focus on Medicinal Chemistry from Assam Downtown University in 2022. He also holds an M. Pharm in Pharmaceutical Chemistry from The Tamil Nadu Dr. MGR Medical University (2012) and a B. Pharm from RIPSAT (2003). Additionally, he has graduate diplomas in Clinical Research and Applied and Industrial Biotechnology. Dr. Bhaumik has contributed significantly to pharmaceutical sciences through his authorship and patent holdings. He has authored textbooks such as "A Textbook of Pharmacology II (BP503T)" and "A Textbook of Pharmaceutical Biotechnology (BP605T)". He also holds two UK design patents and seven Indian patents, reflecting his innovative research in the field. In addition to his academic and research pursuits, Dr. Bhaumik has actively participated in national and international conferences, presenting papers and engaging with the broader scientific community. His dedication to continuous learning is evident through his attendance at various faculty development programs, quality improvement programs (18), short-term courses, and workshops (7) organized by reputed universities and institutions. Dr. Asish Bhaumik is currently supervising four Ph.D. scholars in the Department of Pharmaceutical Chemistry at the School of Pharmaceutical Sciences, Girijananda Chowdhury University (GCU), Tezpur.
he has graduate diplomas in Clinical Research and Applied and Industrial Biotechnology. Dr. Bhaumik has contributed significantly to pharmaceutical sciences through his authorship and patent holdings.
He has authored textbooks such as "A Textbook of Pharmacology II (BP503T)" and "A Textbook of Pharmaceutical Biotechnology (BP605T)". He also holds two UK design patents and seven Indian patents, reflecting his innovative research in the field.
In addition to his academic and research pursuits, Dr. Bhaumik has actively participated in national and international conferences, presenting papers and engaging with the broader scientific community
Role of Anthracycline Antibiotics in Clinical Oncology as well as in Cardiac Pharmacology
Anthracyclines, such as doxorubicin and daunorubicin, are potent chemotherapeutic agents effective against various cancers, including leukemias, lymphomas, and solid tumors like breast and lung cancers. Their antitumor activity primarily results from intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. However, their clinical use is limited by significant toxicities, notably cardiotoxicity. The heart's susceptibility is attributed to high mitochondrial content and a propensity for oxidative stress. Dexrazoxane, an iron-chelating agent, has demonstrated cardioprotective effects by reducing oxidative damage. Nonetheless, its use requires careful consideration due to potential risks, including a possible increase in secondary malignancies. Resistance mechanisms, such as P-glycoprotein-mediated drug efflux, pose challenges in treatment efficacy. Strategies like liposomal encapsulation of anthracyclines aim to enhance tumor targeting and reduce systemic toxicity. Liposomal formulations have shown improved pharmacokinetics and reduced cardiotoxicity.